PALO ALTO, Calif. (AP) _ Eiger BioPharmaceuticals Inc. (EIGR) on Thursday reported a loss of $17.5 million in its second quarter.
The Palo Alto, California-based company said it had a loss of 75 cents per share.
The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 78 cents per share.
Eiger BioPharma shares have fallen slightly more than 1% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $10.03, an increase of almost 2% in the last 12 months.